What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
Portfolio Pulse from Benzinga Insights
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 13 analysts over the past three months, showing a range of perspectives from bullish to bearish. The average 12-month price target is $57.69, with a high of $71.00 and a low of $50.00. Recent analyst actions include multiple 'Buy' ratings and some raised price targets.
July 16, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has received a range of analyst ratings, predominantly bullish, with an average 12-month price target of $57.69. Recent actions include multiple 'Buy' ratings and some raised price targets.
The majority of analysts have given 'Buy' ratings, and some have raised their price targets, indicating positive sentiment. The average price target has increased, suggesting potential upside in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100